{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T09:47:12Z","timestamp":1767260832772,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10840-019-00646-4","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T22:07:38Z","timestamp":1573855658000},"page":"141-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Peri-procedural use of direct anticoagulation agents during cardiac device implantation: vitamin K antagonists vs direct oral anticoagulants"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9709-0203","authenticated-orcid":false,"given":"Jayasree","family":"Pillarisetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Maybrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valay","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nivedita","family":"Adabala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Khalafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudharani","family":"Bommana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajwala","family":"Lakkireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu Yeruva","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Gopinathannair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghamitra","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Di Biase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Natale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Saksena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanunjaya","family":"Lakkireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"issue":"9921","key":"646_CR1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet."},{"issue":"10","key":"646_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"key":"646_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1161\/CIRCEP.111.969105","volume":"5","author":"ML Bernard","year":"2012","unstructured":"Bernard ML, Shotwell M, Nietert PJ, Gold MR. Meta-analysis of bleeding complications associated with cardiac rhythm device implantation. Circ Arrhythm Electrophysiol. 2012;5:468\u201374.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"3","key":"646_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1160\/TH14-04-0305","volume":"113","author":"JD Douketis","year":"2015","unstructured":"Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113(3):625\u201332.","journal-title":"Thromb Haemost"},{"key":"646_CR5","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1056\/NEJMoa1302946","volume":"368","author":"DH Birnie","year":"2013","unstructured":"Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. V BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368:2084\u201393.","journal-title":"N Engl J Med"},{"issue":"28","key":"646_CR6","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","volume":"36","author":"R Cappato","year":"2015","unstructured":"Cappato R, Marchlinski FE, Hohnloser SH, et al. VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36(28):1805\u201311.","journal-title":"Eur Heart J"},{"issue":"10","key":"646_CR7","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jacc.2013.11.039","volume":"63","author":"D Lakkireddy","year":"2014","unstructured":"Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2014;63(10):982\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"646_CR8","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.hrthm.2015.02.028","volume":"12","author":"L Di Biase","year":"2015","unstructured":"Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm. 2015;12(6):1162\u20138.","journal-title":"Heart Rhythm"},{"issue":"44","key":"646_CR9","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1093\/eurheartj\/ehy413","volume":"39","author":"DH Birnie","year":"2018","unstructured":"Birnie DH, Healey JS, Wells GA, Ayala-Paredes F, Coutu B, Sumner GL, et al. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur Heart J. 2018;39(44):3973\u20139.","journal-title":"Eur Heart J"},{"key":"646_CR10","doi-asserted-by":"crossref","unstructured":"Rowley CP, Bernard ML, Brabham WW et al. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol 2013;111(8):1165-1168.","DOI":"10.1016\/j.amjcard.2012.12.046"},{"issue":"10","key":"646_CR11","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/jce.12214","volume":"24","author":"JM Jennings","year":"2013","unstructured":"Jennings JM, Robinaux R, McElderry HT, et al. Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin. J Cardiovasc Electrophysiol. 2013;24(10):1125\u20139.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"7","key":"646_CR12","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/europace\/eut423","volume":"16","author":"J Kosiuk","year":"2014","unstructured":"Kosiuk J, Koutalas E, Doering M, Sommer P, Rolf S, Breithardt OA, et al. Treatment with direct oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. Europace. 2014;16(7):1028\u201332.","journal-title":"Europace."},{"issue":"10","key":"646_CR13","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1253\/circj.CJ-14-0665","volume":"78","author":"J Kosiuk","year":"2014","unstructured":"Kosiuk J, Koutalas E, Doering M, et al. Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study. Circ J. 2014;78(10):2402\u20137.","journal-title":"Circ J"},{"issue":"1","key":"646_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/187152571201141201091848","volume":"12","author":"RM da Silva","year":"2014","unstructured":"da Silva RM. Direct oral anticoagulants in non-valvular atrial fibrillation. Cardiovasc Hematol Agents Med Chem. 2014;12(1):3\u20138.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"646_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.cjca.2013.11.027","volume":"30","author":"T Nascimento","year":"2014","unstructured":"Nascimento T, Birnie DH, Healey JS, Verma A, Joza J, Bernier ML, et al. Managing direct oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey. Can J Cardiol. 2014;30:231\u20136.","journal-title":"Can J Cardiol"},{"key":"646_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jacc.2012.09.057","volume":"61","author":"MR Patel","year":"2013","unstructured":"Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the rocket af trial (rivaroxaban once-daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2013;61:651\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"646_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129:837\u201347.","journal-title":"Circulation."},{"issue":"22","key":"646_CR18","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-019-00646-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10840-019-00646-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-019-00646-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T16:28:01Z","timestamp":1612369681000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10840-019-00646-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["646"],"URL":"https:\/\/doi.org\/10.1007\/s10840-019-00646-4","relation":{},"ISSN":["1383-875X","1572-8595"],"issn-type":[{"type":"print","value":"1383-875X"},{"type":"electronic","value":"1572-8595"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"16 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Lakkireddy is a speaker for Janssen, Boehringer Ingelheim, and Pfizer\/Bristol-Myers Squibb. Dr. Luigi Di Biase is a consultant to Pfizer\/Bristol-Myers Squibb. Dr. Madhu Reddy is a speaker for Pfizer\/Bristol-Myers Squibb. Dr. Gopinathannair is a speaker for Pfizer\/Bristol-Myers Squibb. Dr. Saksena held a research grant from Daiichi Sankyo. All other authors have no relevant conflict of interest to disclose.The work is original and is not published elsewhere.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}